Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

 In November, I wrote that Lilly would likely overtake Merck by late 2026 under base-case assumptions. It happened a year early. And Lilly’s 2026 guidance of $80–$83 billion is already running ahead of that model’s base case of $77.2 billion. For context, Lilly posted $24.5 billion in revenue in 2020. In five years, it… The post Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025 appeared first on Drug Discovery and Development.

Continue reading →